Business Wire

ADVA-NETWORK-SECURITY

20.3.2024 14:01:29 CET | Business Wire | Press release

Share
Adva Network Security launches strategic project within European collaboration to create sovereign clouds

Adva Network Security announced today that it is launching a nationally funded project to develop cloud-optimized, secure network access technology. As part of the Important Projects of Common European Interest (IPCEI), a comprehensive funding initiative is underway to create scalable, real-time and open Next-Generation Cloud Infrastructure and Services (IPCEI-CIS) aimed at ensuring digital sovereignty. Among the 19 German companies participating, Adva Network Security is responsible for developing highly secure network access technology featuring an integrated edge cloud and software solution for robust operation. The solution will be an essential component of a European independent cloud platform, enabling the rapid processing of mission-critical and sensitive data at the network edge.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240320831952/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Funded by the European Union – NextGenerationEU (Graphic: Business Wire)

“The security of mission-critical networks poses major challenges for operators: Quantum computing threatens to compromise established security mechanisms, while the push for digitization requires fast and trusted data processing at the edge of networks. Our project within IPCEI-CIS addresses both of these problems and offers very simple operation through automation,” said Wolfgang Keil, senior director of cybersecurity project management at Adva Network Security. “Leveraging our experience in quantum security, protected hosting and the operation of high-security networks, we’re developing highly secure access to the European cloud. This includes protected hosting of virtualized network functions at the edge, enabling sensitive data to be processed safely and quickly on-site before being transferred securely to the cloud.”

The TRUsted cloud connectivity for automated Endpoint SECurity (TRUE-SEC) project was launched on January 1, 2024, and will run for three years. It is funded by the Federal Ministry for Economic Affairs and Climate Protection based on a resolution of the German Bundestag and financed by the European Union. Its mission is to create an innovative solution for secure network access. Renowned for its expertise in the high-security network domain, Adva Network Security has been entrusted with developing this critical component for an end-to-end European cloud infrastructure. In collaboration with many project partners, IPCEI-CIS aims to establish a standardized, open and sustainable cloud infrastructure that ensures future-proof security for data services that are compliant with stringent regulatory requirements. The initiative marks a crucial step in advancing autonomous and sovereign cloud technology across Europe.

“Already deployed across numerous high-security networks, our technology safeguards some of the most sensitive and mission-critical data. Yet, new threat scenarios require continuous improvement. Through our participation in the IPCEI-CIS initiative, we’re making an important contribution to the sovereignty of European cloud infrastructure and services,” commented Michael Roth, GM of Adva Network Security. “The funding will enable us to expand our competence center for network security in Berlin. Our growing team of cybersecurity and network specialists is playing a vital role in driving the security – and thereby the acceptance – of cloud services through innovative and technologically sophisticated solutions. We’re proud to be able to make this contribution and honored to help shape Germany’s digital future.”

About Adva Network Security

Adva Network Security has built a fierce reputation for protecting packet optical networks. We pioneered low-latency, multi-layer encryption solutions that are right now safeguarding data in motion for many mission-critical applications. Our ConnectGuard security technology is even combating tomorrow’s quantum security threats. Built by the industry’s leading security experts, our German-based organization helps organizations and government agencies security-harden their networks to ensure critical infrastructure is protected against cyber threats. Our development and manufacturing processes, as well as our security solutions, have been approved and certified by leading governmental security agencies. For more information on how we can help you, please visit www.advasecurity.com.

Published by
Adva Network Security GmbH, Berlin, Germany
www.advasecurity.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240320831952/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping11.8.2026 07:00:00 CEST | Press release

Galderma has introduced the first-and-only shaper to the hyaluronic acid (HA) market with Restylane Shaype, now approved in the European Union (EU) for chin augmentation1 Restylane Shaype is the firmest HA gel available, powered by new NASHA HD™ technology, engineered to build and shape on bone for instant, natural-looking lower-face shaping from any angle1-3 It is the latest addition to the innovative Restylane portfolio – the world’s most diverse range of hyaluronic acid injectables designed to meet evolving aesthetic needs, backed by three decades of science4 Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin region. Engineered for deep injection to build and shape on bone, Restylane Shaype delivers a unique bone-mimicking effect, enabling immediate, natural-looking structural enhancement in the lower face without surgery.1-3 This press release features multimedia. View the

Stonebranch is Again Named a Leader in the 2026 Gartner® Magic Quadrant™ for Service Orchestration and Automation Platforms (SOAPs)10.8.2026 17:00:00 CEST | Press release

Gartner recognizes Stonebranch as a Leader for the third consecutive year based on Completeness of Vision and Ability to Execute. Stonebranch, a leading provider of service orchestration and automation solutions, today announced that it has once again been positioned by Gartner as a Leader in the Magic Quadrant for Service Orchestration and Automation Platforms (SOAPs) for its offering, Universal Automation Center™ (UAC).1 “We’re pleased to be recognized as a Leader for the third year in a row,” said Giuseppe Damiani, CEO at Stonebranch. “To us, this recognition reflects our advancements in helping enterprises orchestrate increasingly complex IT operations with confidence. As organizations modernize their automation strategies and adopt AI, UAC provides the centralized orchestration control plane required to unify traditional automation with AI models and agentic systems. With built-in capabilities like Robi AI, UAC’s agentic copilot, we’re making it easier than ever for teams to build

Frontgrade Expands Huntsville Presence with Advanced R&D Center Supporting Next-Generation Space and Defense Missions10.8.2026 16:09:00 CEST | Press release

New facility in Cummings Research Park brings engineering closer to customers while advancing mission processing technologies and strengthening Frontgrade's long-term investment in Huntsville Frontgrade Technologies ("Frontgrade"), a leading provider of mission-critical electronics and integrated technologies, today announced the opening of its eighth U.S. location in Huntsville, Alabama. Located in Cummings Research Park, the new Advanced Research & Development Center will accelerate the development of next-generation mission processing technologies supporting critical space, defense, intelligence, and national security missions. The Huntsville center expands Frontgrade's engineering capabilities while placing research teams closer to customers, government organizations, industry partners, and leading academic institutions. By working within one of the nation's premier aerospace and defense ecosystems, Frontgrade will accelerate technology development, strengthen customer collaboratio

Brightfin Appoints Preeti Shukla as Chief Product and AI Officer10.8.2026 15:00:00 CEST | Press release

Enterprise AI SaaS leader to accelerate Brightfin's AI-Native platform for IT financial management Brightfin, the only IT Financial Management (ITFM) and Technology Expense Management solution built natively on ServiceNow, today announced the appointment of Preeti Shukla as Chief Product and AI Officer (CPAIO). In this newly created role, Shukla will lead product strategy and artificial intelligence across the Brightfin platform, advancing the company's mission to make every technology decision grounded in financial truth, operational clarity, and intelligent automation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260810283143/en/ Preeti Shukla, CPAIO of Brightfin Shukla brings two decades of experience building and scaling customer-facing, enterprise-grade B2B SaaS, fintech, and marketplace products across Fortune 100 companies and high-growth startups, including leadership roles at Workday and Oracle. A recognized autho

BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration10.8.2026 12:00:00 CEST | Press release

Clinical collaboration enables novel combinations of select BeOne oncology assets with four Revolution Medicines clinical-stage RAS(ON) inhibitors for RAS-addicted cancersRegional rights agreement provides BeOne with exclusive development and commercialization rights to four Revolution Medicines clinical assets in select Asian markets BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, and Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced a multi-part collaboration including: a clinical collaboration to evaluate drug combinations incorporating select clinical-stage oncology assets from BeOne with any of Revolution Medicines’ four clinical RAS(ON) inhibitors, and a separate regional rights agreement granting BeOne exclusive development and commercialization rights to these Revolution Medicines assets in select Asian markets. Clinical

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye